Significance of Earlier Initiation of Chemotherapy for Lung Cancer Complicated with Primary or Secondary Nephrotic Syndrome following Its Appropriate Differential Diagnosis

We encountered a case of primary lung cancer complicated with membranous nephropathy as primary nephrotic syndrome. Because treatment approaches vary greatly for primary and secondary nephrotic syndrome, a renal biopsy was performed for diagnosis. Much time was required to make a definitive diagnosis of primary nephrotic syndrome, as opposed to paraneoplastic nephrotic syndrome. Consequently, the subsequent chemotherapy was ineffective and caused significant toxicity due to reduced performance status (PS) and progression of hypoalbuminemia. Therefore, it is imperative that a diagnosis be made and treatment be initiated without delay before PS declines and hypoalbuminemia progresses.

[1]  S. Kirsa,et al.  Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services , 2016, Internal medicine journal.

[2]  O. Arrieta,et al.  Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study , 2010, BMC Cancer.

[3]  Mats O Karlsson,et al.  Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: Comparison across Anticancer Drugs , 2006, Clinical Cancer Research.

[4]  G. Lyman,et al.  Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP‐R, or CNOP chemotherapy for intermediate‐grade non‐Hodgkin lymphoma , 2003, Cancer.

[5]  F. Goldwasser,et al.  Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  N. Milman,et al.  Prevalence and prognostic significance of proteinuria in patients with lung cancer. , 1996, Acta oncologica.

[7]  M. Haas,et al.  IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  M. Schwartz,et al.  Membranous glomerulonephritis and malignancy. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  J. Crowley,et al.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Averbuch,et al.  Nephrotic syndrome complicating adenocarcinoma of the lung with resolution after resection. , 1991, The Annals of thoracic surgery.

[11]  Y. Hamashima,et al.  Distribution of IgG subclasses in membranous nephropathy. , 1984, Clinical and experimental immunology.

[12]  K E Stanley,et al.  Prognostic factors for survival in patients with inoperable lung cancer. , 1980, Journal of the National Cancer Institute.

[13]  J. Lee,et al.  The association of cancer and the nephrotic syndrome. , 1966, Annals of internal medicine.